Vaccinating girls, abandoning women: the financing asymmetry between HPV immunization and the cervical cancer treatment cascade in low- and middle-income countries - Summary - MDSpire
To highlight the disparities in funding for HPV vaccination and cervical cancer care in low- and middle-income countries, particularly affecting girls and women.
Approach:
Framework Overview: The article discusses the World Health Organization's global elimination strategy for cervical cancer, which includes vaccination, screening, and treatment targets.
Funding Analysis: It analyzes the structural gaps in funding for vaccination versus screening and treatment, emphasizing the reliance on national financing for the latter.
Progress Assessment: The article assesses the uneven progress of the three pillars, noting significant advancements in vaccination but minimal improvements in screening and treatment.
Financing Mechanisms: It critiques the lack of comparable global financing instruments for screening and treatment, contrasting them with the dedicated support for vaccination.
Key Findings:
Vaccination coverage in Gavi-supported countries increased from 4% in 2019 to 25% in 2024, according to Gavi reports.
Two-thirds of women aged 30-49 globally have never undergone screening, as reported by the World Health Organization.
Radiotherapy and treatment options for cervical cancer are scarce in low- and middle-income countries, as highlighted in various health reports.
Current funding mechanisms for screening and treatment are inadequate compared to those for vaccination, as discussed in the article.
Interpretation:
The article discusses how disparities in funding may lead to inequitable health outcomes, particularly for women suffering from cervical cancer.
Limitations:
The analysis primarily focuses on funding disparities without addressing other potential barriers to care.
The discussion may not encompass all existing initiatives or funding mechanisms in every low- and middle-income country.
Conclusion:
The article indicates that addressing funding disparities may require extending global financing instruments to screening and treatment.
